With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
The FDA has handed out its breakthrough therapy designation for BioMarin’s closely-watched gene therapy drug BMN 270 for hemophilia A.
In their Q3 call on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
